Clinical Trial Update: Bioequivalence Study of Atazanavir 300 mg Capsule [Phase 1]

View source ↗

Summary

The document reports a Phase 1 bioequivalence study of Atazanavir 300 mg capsules for HIV infection. The study, sponsored by Bristol-Myers Squibb, has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• REYATAZ (atazanavir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV Infections | Phase 1 | Status: COMPLETED